Megace, Megace ES
Classifications: antineoplastic; hormone; progestin; Therapeutic: antineoplastic; progestin
Pregnancy Category: X (oral suspension) and D (tablets)
40 mg/mL, 125 mg/mL suspension; 20 mg, 40 mg tablets
Progestational hormone with antineoplastic properties. Mechanism of action unclear; however, an antiluteinizing effect mediated
via the pituitary has been postulated.
Antineoplastic agent effective for treating breast, renal cell, or endometrial carcinoma. Also effective as an appetite
enhancer. Has a local effect when instilled directly into the endometrial cavity.
Palliative agent for treatment of advanced carcinoma of breast or endometrium. AIDS-related wasting or cachexia.
Diagnostic test for pregnancy; pregnancy category X (oral suspension) and category D (tablet); lactation.
Older adults; severe hepatic disease; diabetes mellitus; renal impairment; thromboembolic disease.
Route & Dosage
|Palliative Treatment for Advanced Breast Cancer
Adult: PO 40 mg q.i.d.
Palliative Treatment for Advanced Endometrial Cancer
Adult: PO 40320 mg/d in divided doses
Adult: PO 200 mg q6h
Adult: PO (suspension) 800 mg q.d. or 625 mg of Megace ES
- Give with meals or food if GI distress occurs.
- Shake oral suspension well before use.
- Store at 15°30° C (59°86° F) in tightly closed container.
Adverse Effects (≥1%)Urogenital:
Vaginal bleeding. Body as a Whole:
Breast tenderness, headache, increased appetite, weight gain, allergic-type reactions (including bronchial asthma). GI:
Abdominal pain, nausea, vomiting. Hematologic:
May increase levels of warfarin;
may decrease renal
clearance of dofetilide.
Appears to be well absorbed from GI tract. Onset:
Onset of objective response in breast cancer
in 68 wk. Peak:
13 h. Duration:
312 mo. Metabolism:
Completely metabolized in liver. Elimination:
5778% of dose excreted in urine within 10 d.
Assessment & Drug Effects
- Monitor weight periodically.
- Notify physician if abdominal pain, headache, nausea, vomiting, or breast tenderness become pronounced.
- Monitor for allergic reactions, including breathing distress characteristic of asthma, rash, urticaria, anaphylaxis, tachypnea,
anxiety. Stop medication if they appear and notify physician.
Patient & Family Education
- Use contraception measures during therapy for carcinoma.
- Learn breast self-examination.
- Learn S&S of thrombophlebitis (see Appendix F).
- Review package insert to ensure understanding of megestrol therapy.